Member Info for stephen11

Thanks for presentation link ART123.

Anyone got a link?

I'll me holding onto to these little golden tickets.

A blind man on a galloping horse could make money on this one!

GLA.

What’s the rough, ballpark market value of Chuditch?

Try a Long Island Iced tea - 5 types of white spirit and coke

The plot thickens. Let us know how you get on. This is not good - what, for example if you'd been a purchase manager from a large corporation and wanted to place an order. This doesn't bode confidence?
GLA.

Very peculiar DSFLAT,

Did the receptionist not even offer to pass you on to a sales specialist in this field?

They all add up

She's just BOILED over the 40%+ mark.

According to the share trade board!

Could we end up 50% up for day when the dust settles.

GLA.

BOIL is building a head of steam.

It's back on the BOIL!

It’s the trolls I called negative. I don’t mind legitimate posters who post concerns in a constructive manner. Read my posts. I have also posted questioning Budd’s management and the lack of commercialisation.

Thanks for the info Elir and Wolves.

Thanks BigAl,

I remember that and thought your figures to be spot on, had we received the FDA approval, but the yanks preferred their own tests, if I remember correctly, and the approval system was really slow as well. I’ve tried to filter as many of the trolls as possible, but negative people do pop up every now and again.

Keep the faith BigAl.

Better days to come I hope!

DSFLAT,

I am reluctant to run estimates on future revenue due to GDRs failure to take any products to sales/commercialisation in any great level over the last 3 years (Check the last 3 years accounts if you want to do your own DD).

This has been very frustrating, though I live in hope that things will change with the stroke and hearing loss products. Unlike the COVID products, that were late to the party in a saturated market, the stroke and hearing loss products our world firsts in their respective fields.

So, if or when sales start for the stroke products (once we get over all the regulatory hurdles), they might look something like this.
- If 3.16M prescriptions were dispensed each year in the UK for Clopidogrel, let's say as a conservative estimate 500,000 of these patients were receiving the drug for the first time. These people need to know if Clopidogrel is a suitable drug for them to take, so would take GDRs test
- Let's be really cautious on price. The hearing loss test is supposed to cost £80 per baby. In the absence of any company figures let's say the stroke test costs £50 per person
- 500,000 x £50 = £25 million in yearly revenue for the UK alone (only if the stroke test gets written into NICE guidelines)

As always DYOR. What's everyone's thoughts on these figures - conservative or too extravagant?

GLA.

Stephen11.

The curiosity got the better of me.

Between January 1999 to September 2017 in primary care practices in the UK 57 million prescriptions for Clopidogrel were dispensed. Although it must be said many of these would be repeat prescriptions, this still averages around 3.16m per year. I don't know how many of these per year would be first time prescriptions.

GDRs test aims to determine whether CYP2C19 loss-of-function (LoF) alleles increase risk of ischaemic stroke and myocardial infarction (MI) in patients prescribed clopidogrel. Therefore, it would be needed for existing patients and new ones presumable. Does anyone remember cost per test?

With the numbers above it could produce a significant revenue stream!

GLA.

DSFLAT,

This type of info is usually available in medical journals, who would publish such information in research papers.

I'll have a look on Google Scholar tomorrow at some stage. Would be interesting to know.

ATB

Stephen11.

It's been long enough. How much new info do the regulatory authorities need?

This share has been in my bottom drawer for the last year and i'm now putting it in the cupboard under the stairs. If it helps i could re-home the bats and moles there as well?

GLA.

Was the 28th 0ct 2021 and the subsequent investormeetcompany presentation was the 9th November 2021, so hopefully not long now until we know when the final results will be announced.

Hopefully this week!

GLA.